Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.63 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.54 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.40 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13002136 | 0.98 | MEN1 (0.62) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002135 | 0.98 | MEN1 (0.62) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL3516120 | 0.95 | MEN1 (0.57) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL6468921 | 0.91 | MEN1 (0.60) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002137 | 0.88 | MEN1 (0.49) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002128 | 0.86 | MEN1 (0.55) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL14089180 | 0.85 | MEN1 (0.52) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002131 | 0.84 | MEN1 (0.57) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002138 | 0.81 | PLA2G2A (0.54) | MEN1KMT2APAK1PLA2G2APLA2G5 | |
| SCHEMBL13002140 | 0.81 | PLA2G2A (0.54) | MEN1KMT2APAK1PLA2G2APLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | claimed |
| US-20260002121-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | CHILDRENS HOSPITAL MED CT (US) | 2026-01-01 | — | — | US | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| WO-2024218058-A1 | NOVEL COMPOUNDS AS α4β7 INHIBITORS | EVOTEC INTERNATIONAL GMBH (DE) | 2024-10-24 | — | — | WO | claimed |
| EP-4440586-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | Children's Hospital Medical Center (US) | 2024-10-09 | — | — | EP | claimed |
| WO-2023102133-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2023-06-08 | — | — | WO | claimed |
| US-20220275341-A1 | ORGANOID MESODERM LINEAGE DIVERSIFICATION | CHILDRENS HOSPITAL MED CT (US) | 2022-09-01 | — | — | US | claimed |
| EP-4022036-A2 | ORGANOID MESODERM LINEAGE DIVERSIFICATION | Children's Hospital Medical Center, Center for Technology Commercialization (US) | 2022-07-06 | — | — | EP | claimed |
| CN-114430774-A | Organoid mesoderm lineage diversification | 儿童医院医学中心 | 2022-05-03 | — | — | CN | claimed |
| EP-4713433-A2 | LIVER ORGANOIDS WITH INTRAHEPATIC SYMPATHETIC NERVES, AND METHODS OF USE THEREOF | Children's Hospital Medical Center (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4698517-A1 | <SUP2/>? <SUB2/>?4?NOVEL COMPOUNDS AS ?? <NS1:SUB>7</NS1:SUB>?INHIBITORS | Evotec International GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| US-20260002121-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | CHILDRENS HOSPITAL MED CT (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | AGAIN BIO APS (DK) | 2025-12-25 | — | — | US | disclosed |
| US-20250340835-A1 | VASCULARIZED BRAIN ORGANOIDS AND METHODS OF MAKING AND USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2009011870-A1 | REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR | THE GENERAL HOSPITAL CORPORATION (US) | 2009-01-22 | — | — | WO | disclosed |
| JP-2005289891-A | PDE1 INHIBITOR | KUBOHARA ZEN | 2005-10-20 | — | — | JP | disclosed |
| US-6888033-B1 | Anti-viral compounds | CYTOCLONAL PHARMACEUTICS, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| EP-0363392-A1 | SUBSTITUTED PHENONE | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 1990-04-18 | — | — | EP | disclosed |
| WO-1988009321-A1 | SUBSTITUTED PHENONE | 3I RESEARCH EXPLOITATION LIMITED (GB) | 1988-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388910-A1 | METHODS FOR ENHANCING MICROBIAL PRODUCTION OF SPECIFIC LENGTH FATTY ALCOHOLS IN THE PRESENCE OF METHANOL | ADH5, ADH1C, ADH1A | MEN1 4581/4885KMT2A 2260/4885PAK1 3759/4885 |
| US-20260002121-A1 | IMPROVED METHODS OF PREPARING DIFFERENT MESODERM CELL TYPES | BMP4, RARB, WNT3A | MEN1 3134/4885KMT2A 2242/4885PAK1 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.